Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer. Onvansertib in combination with irinotecan, fluorouracil (5-FU), and folinic acid (leucovorin; FOLFIRI), plus bevacizumab (Avastin), demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated...